Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker

2006919 citationsJournal Articlebronze Open Access

Authors

Stevo Julius · University of Michigan–Ann Arbor

Shawna D. Nesbitt · The University of Texas Southwestern Medical Center

Brent M. Egan · Medical University of South Carolina

Michael A. Weber · State University of New York

Eric L. Michelson · AstraZeneca (United States)

Niko Kaciroti · University of Michigan–Ann Arbor

Henry R. Black

Abstract

Over a period of four years, stage 1 hypertension developed in nearly two thirds of patients with untreated prehypertension (the placebo group). Treatment of prehypertension with candesartan appeared to be well tolerated and reduced the risk of incident hypertension during the study period. Thus, treatment of prehypertension appears to be feasible. (ClinicalTrials.gov number, NCT00227318.).

Topics & Keywords

Blood Pressure and Hypertension Studies Sodium Intake and Health Hormonal Regulation and Hypertension

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 354, Issue 16, pp. 1685-1697

DOI: 10.1056/nejmoa060838

Field-Weighted Citation Impact: 65.17